Editas Medicine (EDIT) Research & Development (2016 - 2025)
Historic Research & Development for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $19.8 million.
- Editas Medicine's Research & Development fell 5848.99% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year decrease of 4951.68%. This contributed to the annual value of $199.2 million for FY2024, which is 1215.64% up from last year.
- Per Editas Medicine's latest filing, its Research & Development stood at $19.8 million for Q3 2025, which was down 5848.99% from $16.2 million recorded in Q2 2025.
- In the past 5 years, Editas Medicine's Research & Development ranged from a high of $69.6 million in Q4 2023 and a low of $16.2 million during Q2 2025
- Its 5-year average for Research & Development is $39.8 million, with a median of $40.5 million in 2023.
- In the last 5 years, Editas Medicine's Research & Development soared by 8204.1% in 2024 and then plummeted by 7015.13% in 2025.
- Editas Medicine's Research & Development (Quarter) stood at $37.6 million in 2021, then skyrocketed by 38.47% to $52.0 million in 2022, then surged by 33.77% to $69.6 million in 2023, then crashed by 30.11% to $48.6 million in 2024, then tumbled by 59.32% to $19.8 million in 2025.
- Its last three reported values are $19.8 million in Q3 2025, $16.2 million for Q2 2025, and $26.6 million during Q1 2025.